Pure Global
NCT03950830

Disulfiram and Cisplatin in Refractory TGCTs.

Phase II Study of Disulfiram and Cisplatin in Refractory TGCTs.
National Cancer Institute, Slovakia·Phase 2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Germ Cell Tumor
Drug/Device/Intervention
Disulfiram
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
National Cancer Institute, Slovakia
Location
Bratislava, Slovakia
Timeline & enrollment
Phase
Phase 2
Start date
May 14, 2019
End date
Dec 31, 2022
Enrollment
20 participants
Primary outcome

Overall response rate

Summary

Non-randomized, open-label, single center trial to assess efficacy (as measured by overall
 response rate (ORR) by RECIST 1.1 of disulfiram and cisplatin in patients with multiple
 relapsed/refractory germ cell tumors (GCTs).

ICD-10 classifications
Malignant neoplasmsMalignant neoplasm: JejunumMalignant neoplasm: PrepuceMalignant neoplasm: Female genital organ, unspecifiedMalignant neoplasm: Vulva, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT03950830
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT03950830 through Pure Global AI's free database. This Phase 2 trial is sponsored by National Cancer Institute, Slovakia and is currently Recruiting. The study focuses on Germ Cell Tumor. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.